期刊
GASTROENTEROLOGY
卷 134, 期 2, 页码 405-415出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2007.11.036
关键词
-
资金
- Intramural NIH HHS [Z01 DK054500-11] Funding Source: Medline
- PHS HHS [R0-1 AIO60449] Funding Source: Medline
Treatment of chronic hepatitis B virus (HBV) infection is aimed at suppressing viral replication to the lowest possible level, and thereby to halt the progression of liver disease and prevent the onset of complications. Two categories of drugs are used in HBV therapy: the interferons, including standard interferon alfa or pegylated interferon alfa, and specific nucleoside or nucleotide HBV inhibitors that target the reverse-transcriptase function of HBV-DNA polymerase. The reported results of clinical trials have used varying definitions of efficacy, failure, and resistance based on different measures of virologic responses. This article discusses HBV virologic markers and tests, and their optimal use both for planning and reporting clinical trials and in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据